vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Zeta Global Holdings Corp. (ZETA). Click either name above to swap in a different company.
Zeta Global Holdings Corp. is the larger business by last-quarter revenue ($394.6M vs $284.0M, roughly 1.4× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 1.7%, a 94.7% gap on every dollar of revenue. On growth, Zeta Global Holdings Corp. posted the faster year-over-year revenue change (25.4% vs 9.4%). Over the past eight quarters, Zeta Global Holdings Corp.'s revenue compounded faster (42.3% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Zeta Global Holdings Corp. is an American marketing technology company which was founded in 2007. Zeta offers companies a suite of multichannel marketing tools focused on creating, maintaining, and monetizing customer relationships. The company went public on the New York Stock Exchange on June 10, 2021, at a US$1.7 billion valuation.
ACAD vs ZETA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $394.6M |
| Net Profit | $273.6M | $6.5M |
| Gross Margin | 90.8% | 59.5% |
| Operating Margin | 6.1% | 4.5% |
| Net Margin | 96.3% | 1.7% |
| Revenue YoY | 9.4% | 25.4% |
| Net Profit YoY | 90.3% | -57.1% |
| EPS (diluted) | $1.61 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $394.6M | ||
| Q3 25 | $278.6M | $337.2M | ||
| Q2 25 | $264.6M | $308.4M | ||
| Q1 25 | $244.3M | $264.4M | ||
| Q4 24 | $259.6M | $314.7M | ||
| Q3 24 | $250.4M | $268.3M | ||
| Q2 24 | $242.0M | $227.8M | ||
| Q1 24 | $205.8M | $194.9M |
| Q4 25 | $273.6M | $6.5M | ||
| Q3 25 | $71.8M | $-3.6M | ||
| Q2 25 | $26.7M | $-12.8M | ||
| Q1 25 | $19.0M | $-21.6M | ||
| Q4 24 | $143.7M | $15.2M | ||
| Q3 24 | $32.8M | $-17.4M | ||
| Q2 24 | $33.4M | $-28.1M | ||
| Q1 24 | $16.6M | $-39.6M |
| Q4 25 | 90.8% | 59.5% | ||
| Q3 25 | 92.2% | 60.5% | ||
| Q2 25 | 92.2% | 62.1% | ||
| Q1 25 | 91.7% | 60.9% | ||
| Q4 24 | 91.6% | 60.0% | ||
| Q3 24 | 92.5% | 60.6% | ||
| Q2 24 | 92.5% | 60.0% | ||
| Q1 24 | 88.8% | 60.6% |
| Q4 25 | 6.1% | 4.5% | ||
| Q3 25 | 12.8% | 2.6% | ||
| Q2 25 | 12.2% | -1.7% | ||
| Q1 25 | 7.9% | -6.1% | ||
| Q4 24 | 59.1% | 2.2% | ||
| Q3 24 | 12.6% | -4.6% | ||
| Q2 24 | 12.6% | -11.7% | ||
| Q1 24 | 7.4% | -18.4% |
| Q4 25 | 96.3% | 1.7% | ||
| Q3 25 | 25.8% | -1.1% | ||
| Q2 25 | 10.1% | -4.2% | ||
| Q1 25 | 7.8% | -8.2% | ||
| Q4 24 | 55.4% | 4.8% | ||
| Q3 24 | 13.1% | -6.5% | ||
| Q2 24 | 13.8% | -12.3% | ||
| Q1 24 | 8.0% | -20.3% |
| Q4 25 | $1.61 | $0.04 | ||
| Q3 25 | $0.42 | $-0.02 | ||
| Q2 25 | $0.16 | $-0.06 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.86 | $0.10 | ||
| Q3 24 | $0.20 | $-0.09 | ||
| Q2 24 | $0.20 | $-0.16 | ||
| Q1 24 | $0.10 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $319.8M |
| Total DebtLower is stronger | — | $197.1M |
| Stockholders' EquityBook value | $1.2B | $804.6M |
| Total Assets | $1.6B | $1.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $319.8M | ||
| Q3 25 | $258.0M | $385.2M | ||
| Q2 25 | $253.6M | $365.3M | ||
| Q1 25 | $217.7M | $364.4M | ||
| Q4 24 | $319.6M | $366.2M | ||
| Q3 24 | $155.1M | $418.5M | ||
| Q2 24 | $177.1M | $154.7M | ||
| Q1 24 | $204.7M | $141.6M |
| Q4 25 | — | $197.1M | ||
| Q3 25 | — | $196.9M | ||
| Q2 25 | — | $196.7M | ||
| Q1 25 | — | $196.5M | ||
| Q4 24 | — | $196.3M | ||
| Q3 24 | — | $196.1M | ||
| Q2 24 | — | $184.4M | ||
| Q1 24 | — | $184.2M |
| Q4 25 | $1.2B | $804.6M | ||
| Q3 25 | $917.3M | $689.2M | ||
| Q2 25 | $822.4M | $673.3M | ||
| Q1 25 | $765.2M | $676.6M | ||
| Q4 24 | $732.8M | $676.8M | ||
| Q3 24 | $577.2M | $474.9M | ||
| Q2 24 | $516.7M | $217.0M | ||
| Q1 24 | $464.0M | $191.6M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $976.9M | $869.1M | ||
| Q2 24 | $914.1M | $583.9M | ||
| Q1 24 | $855.1M | $550.3M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.41× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.96× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $64.1M |
| Free Cash FlowOCF − Capex | — | $60.9M |
| FCF MarginFCF / Revenue | — | 15.4% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | -0.18× | 9.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | $185.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $64.1M | ||
| Q3 25 | $74.3M | $57.9M | ||
| Q2 25 | $64.0M | $42.0M | ||
| Q1 25 | $20.3M | $34.8M | ||
| Q4 24 | $40.4M | $43.7M | ||
| Q3 24 | $63.2M | $34.4M | ||
| Q2 24 | $25.0M | $31.1M | ||
| Q1 24 | $29.1M | $24.7M |
| Q4 25 | — | $60.9M | ||
| Q3 25 | $73.9M | $52.4M | ||
| Q2 25 | — | $39.7M | ||
| Q1 25 | — | $32.1M | ||
| Q4 24 | — | $35.4M | ||
| Q3 24 | $63.2M | $29.5M | ||
| Q2 24 | — | $24.4M | ||
| Q1 24 | — | $18.9M |
| Q4 25 | — | 15.4% | ||
| Q3 25 | 26.5% | 15.6% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 12.1% | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | 25.2% | 11.0% | ||
| Q2 24 | — | 10.7% | ||
| Q1 24 | — | 9.7% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | 0.1% | 1.6% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | -0.18× | 9.81× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 2.87× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ZETA
Segment breakdown not available.
